Amylin to present obesity pipeline data

San Diego, USA-based Amylin Pharmaceuticals will present new data on its pipeline obesity candidates at the annual scientific meeting of the Obesity Society in Phoenix, Arizona, taking place on October 3-7.

In addition to the firm's lead clinical-stage programs in obesity, pramlintide/metreleptin and AC2307, new findings will also be presented on various preclinical-stage products, including a new Y-family mimetic and a peptide hybrid platform. Additional information will be presented during two corporate-sponsored symposia focused on the emerging peptide hormone approach to the treatment of obesity and the new science and therapeutic research that shows promise to reduce the risk of cardiovascular disease associated with obesity and type 2 diabetes.

"We will be sharing compelling data that demonstrates how our programs have the potential to provide significant weight loss that can be sustained over time," said chief executive Daniel Bradbury. "Our unique neurohormonal approach to obesity, and our deep expertise in peptide hormones, enables us to develop drugs that may help regulate how many calories we eat, burn and store as fat by mimicking the effects of naturally-occurring hormones. Amylin's approach has the potential to achieve significant weight loss with a reduced risk for side effects that are often seen with other obesity treatments," he added.